Advertisement
CGEN or EXAS or MDXG
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CGEN’s FA Score shows that 1 FA rating(s) are green whileEXAS’s FA Score has 0 green FA rating(s), and MDXG’s FA Score reflects 1 green FA rating(s).
- CGEN’s FA Score: 1 green, 4 red.
- EXAS’s FA Score: 0 green, 5 red.
- MDXG’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CGEN’s TA Score shows that 6 TA indicator(s) are bullish while EXAS’s TA Score has 5 bullish TA indicator(s), and MDXG’s TA Score reflects 4 bullish TA indicator(s).
- CGEN’s TA Score: 6 bullish, 2 bearish.
- EXAS’s TA Score: 5 bullish, 4 bearish.
- MDXG’s TA Score: 4 bullish, 6 bearish.
Price Growth
CGEN (@Biotechnology) experienced а +1.46% price change this week, while EXAS (@Medical Specialties) price change was +0.55% , and MDXG (@Biotechnology) price fluctuated -2.68% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was -3.91%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.78%. For the same industry, the average monthly price growth was +5.29%, and the average quarterly price growth was -0.03%.
Reported Earning Dates
CGEN is expected to report earnings on Jul 31, 2025.
EXAS is expected to report earnings on Aug 05, 2025.
MDXG is expected to report earnings on Aug 05, 2025.
Industries' Descriptions
@Biotechnology (+1.05% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (-0.78% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| CGEN | EXAS | MDXG | |
| Capitalization | 130M | 12.8B | 993M |
| EBITDA | -14.41M | 29.3M | 62.1M |
| Gain YTD | -9.150 | 0.516 | -28.274 |
| P/E Ratio | 64.00 | N/A | 24.89 |
| Revenue | 27.9M | 2.5B | 352M |
| Total Cash | 103M | 778M | 106M |
| Total Debt | 2.91M | 2.56B | 18.7M |
CGEN | EXAS | MDXG | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 24 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 44 Fair valued | 68 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 76 | |
SMR RATING 1..100 | 92 | 94 | 40 | |
PRICE GROWTH RATING 1..100 | 81 | 40 | 61 | |
P/E GROWTH RATING 1..100 | 20 | 100 | 12 | |
SEASONALITY SCORE 1..100 | 95 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EXAS's Valuation (44) in the Biotechnology industry is in the same range as MDXG (68) and is somewhat better than the same rating for CGEN (77). This means that EXAS's stock grew similarly to MDXG’s and somewhat faster than CGEN’s over the last 12 months.
MDXG's Profit vs Risk Rating (76) in the Biotechnology industry is in the same range as EXAS (100) and is in the same range as CGEN (100). This means that MDXG's stock grew similarly to EXAS’s and similarly to CGEN’s over the last 12 months.
MDXG's SMR Rating (40) in the Biotechnology industry is somewhat better than the same rating for CGEN (92) and is somewhat better than the same rating for EXAS (94). This means that MDXG's stock grew somewhat faster than CGEN’s and somewhat faster than EXAS’s over the last 12 months.
EXAS's Price Growth Rating (40) in the Biotechnology industry is in the same range as MDXG (61) and is somewhat better than the same rating for CGEN (81). This means that EXAS's stock grew similarly to MDXG’s and somewhat faster than CGEN’s over the last 12 months.
MDXG's P/E Growth Rating (12) in the Biotechnology industry is in the same range as CGEN (20) and is significantly better than the same rating for EXAS (100). This means that MDXG's stock grew similarly to CGEN’s and significantly faster than EXAS’s over the last 12 months.
| CGEN | EXAS | MDXG | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 72% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 82% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 81% | 3 days ago 77% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 82% | N/A | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 72% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 75% | 2 days ago 77% |
| Advances ODDS (%) | 8 days ago 81% | 4 days ago 70% | 4 days ago 78% |
| Declines ODDS (%) | 17 days ago 89% | 2 days ago 82% | 2 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 78% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 66% | 2 days ago 73% | 2 days ago 80% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DSL | 12.01 | 0.04 | +0.33% |
| DOUBLELINE Income SOLUTIONS FUND | |||
| IVV | 585.76 | 0.09 | +0.02% |
| iShares Core S&P 500 ETF | |||
| JHS | 11.16 | N/A | N/A |
| John Hancock Income Securities Trust Capital Stock | |||
| CAOS | 88.53 | N/A | N/A |
| Alpha Architect Tail Risk ETF | |||
| SDEM | 26.60 | N/A | N/A |
| Global X MSCI SuperDividend® Em Mkts ETF | |||
CGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with NURPF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then NURPF could also see price increases.
| Ticker / NAME | Correlation To CGEN | 1D Price Change % | ||
|---|---|---|---|---|
| CGEN | 100% | N/A | ||
| NURPF - CGEN | 46% Loosely correlated | N/A | ||
| ASPHF - CGEN | 41% Loosely correlated | N/A | ||
| ORMP - CGEN | 40% Loosely correlated | N/A | ||
| BDTX - CGEN | 40% Loosely correlated | +1.48% | ||
| ITOS - CGEN | 37% Loosely correlated | +5.72% | ||
More | ||||
EXAS and
Correlation & Price change
A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with QGEN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then QGEN could also see price increases.
| Ticker / NAME | Correlation To EXAS | 1D Price Change % | ||
|---|---|---|---|---|
| EXAS | 100% | -0.72% | ||
| QGEN - EXAS | 55% Loosely correlated | N/A | ||
| RGEN - EXAS | 55% Loosely correlated | +0.20% | ||
| CDNA - EXAS | 33% Poorly correlated | N/A | ||
| ILMN - EXAS | 32% Poorly correlated | +1.47% | ||
| FNA - EXAS | 32% Poorly correlated | N/A | ||
More | ||||
MDXG and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To MDXG | 1D Price Change % | ||
|---|---|---|---|---|
| MDXG | 100% | N/A | ||
| AXON - MDXG | 47% Loosely correlated | N/A | ||
| VCYT - MDXG | 42% Loosely correlated | N/A | ||
| ARRY - MDXG | 39% Loosely correlated | N/A | ||
| RAPT - MDXG | 38% Loosely correlated | N/A | ||
| INM - MDXG | 38% Loosely correlated | +1.85% | ||
More | ||||